골다공증성 고관절부 골절 환자에서 다음에 발생한 고관절부 골절
Subsequent Hip Fracture in Osteoporotic Hip Fracture Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: A significant number of patients who had a previous surgical treatment in the hip area experience subsequent hip fracture (SHF) on the opposite side. This study aims to analyze the risk factors and the correlation between osteoporosis and SHF on the opposite side by measuring bone mineral density (BMD) and treatment provided by risedronate for the prevention of SHF. Material & Methods: We studied 475 patients without treatment who had unilateral hip and included following: death, SHF, alcoholism, living alone, dementia, dizziness, health status, osteoporotic treatment after fracture and BMD from March 1997 to June 2006. We selected 26 patients with SHF and the other 26 patients without SHF who had similar age, sex, BMI, BMD, diagnosis, treatment and follow up. The average follow up was 6.4 years (4～12 years) and 6.2 years (4～12 years). Results: The mortality rate was 138 (28.0%). There was no significant difference in the criteria listed earlier. The average T-score with SHF was -5.13 (-3.2～-6.6, S.D. 0.34) and -5.02 (-3.2～-6.8) without SHF. The BMD at time of fracture has no statistical difference between two groups (P>0.05). 7 patients (26.9%) were prescribed risedronate with SHF and 14 patients (53.8%) received the same treatment without SHF. There was a statistical relation whether they were treated for osteoporosis (P=0.048). The average BMD with SHF was -5.13 and without SHF was -5.02 (P>0.05). Conclusion: Although primary surgical treatments are important for excellent outcome, osteoporotic treatment is as important to prevent SHF in prior hip fracture.
Abstract
Objectives: A significant number of patients who had a previous surgical treatment in the hip area experience subsequent hip fracture (SHF) on the opposite side. This study aims to analyze the risk factors and the correlation between osteoporosis and SHF on the opposite side by measuring bone mineral density (BMD) and treatment provided by risedronate for the prevention of SHF. Material & Methods: We studied 475 patients without treatment who had unilateral hip and included following: death, SHF, alcoholism, living alone, dementia, dizziness, health status, osteoporotic treatment after fracture and BMD from March 1997 to June 2006. We selected 26 patients with SHF and the other 26 patients without SHF who had similar age, sex, BMI, BMD, diagnosis, treatment and follow up. The average follow up was 6.4 years (4～12 years) and 6.2 years (4～12 years). Results: The mortality rate was 138 (28.0%). There was no significant difference in the criteria listed earlier. The average T-score with SHF was -5.13 (-3.2～-6.6, S.D. 0.34) and -5.02 (-3.2～-6.8) without SHF. The BMD at time of fracture has no statistical difference between two groups (P>0.05). 7 patients (26.9%) were prescribed risedronate with SHF and 14 patients (53.8%) received the same treatment without SHF. There was a statistical relation whether they were treated for osteoporosis (P=0.048). The average BMD with SHF was -5.13 and without SHF was -5.02 (P>0.05). Conclusion: Although primary surgical treatments are important for excellent outcome, osteoporotic treatment is as important to prevent SHF in prior hip fracture.
참고문헌 (20)
- Cooper C, "Hip fractures in the elderly: a world-wide projection", Osteoporos Int, 2, pp.285~289 (1992)
- Melton LJ 3rd, "Perspective. How many women have osteoporosis?", J Bone Miner Res, 7, pp.1005~1010 (1992)
- Hodsman AB, "10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program", Arch Intern Med, 168, pp.2261~2267 (2008)
- 이성락, "고관절 주위골절로 인한 사망률 및 활동성 -전향적 연구-", 대한정형외과학회지, 40(4), pp.423~427 (2005), 대한정형외과학회
- Gardner MJ, "Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial", J Bone J Surg, 87-A, pp.3~7 (2005)
- Juby AG, "Evaluation of osteoporosis treatment in seniors after hip fracture", Osteoporos Int, 13, pp.205~210 (2002)
- Cummings SR, "Epidemiology of osteoporosis and osteoporotic fractures", Epidemiol Rev, 7, pp.178~208 (1985)
- Eastwood EA, "Patients with hip fracture: subgroups and their outcomes", J Am Geriatr Soc, 50, pp.1240~1249 (2002)
- Melton LJ, "Epidemiology and costs of osteoporotic fractures. In second international conference on osteoporosis", Social and Clinical Aspects, pp.23~31 (1986)
- Boston DA, "Bilateral fractures of the femoral neck", Injury, 14, pp.207~210 (1982)
- Bell GH, "Variations in strength of vertebrae with age and their relation to osteoporosis", Calcif Tissue Res, 1, pp.75~86 (1967)
- Carter DR, "Bone compressive strength: the influence of density and strain rate", Science, 194, pp.1174~1176 (1976)
- Ryg J, "Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001", J Bone Miner Res, 24, pp.1299~1307 (2009)
- Cook PJ, "Fractured femurs, falls and bone disorders", J R Coll Physicians Lond, 16, pp.45~49 (1982)
- Jung ES, "Differences of bone mineral density between osteoporotic group with or without compression fracture of the spine", J Korean Society Fracture, 11, pp.629~633 (1998)
- "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group", World Health Organ Tech Rep Ser, 843, pp.1~129 (1994)
- 장작, "노년층 고관절부 골절과 골다공증의 상관 관계", 대한고관절학회지, 20(4), pp.299~304 (2008), 대한고관절학회
- McClung MR, "Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group", N Engl J Med, 344, pp.333~340 (2001)
- Bilezikian JP, "Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis", AM J Med, 122, pp.14~21 (2009)
- Kanis JA, "A meta-analysis of previous fracture and subsequent fracture risk", Bone, 35, pp.375~382 (2004)